CFO
SUPN icon

CVA Family Office’s Supernus Pharmaceuticals SUPN Stock Holding History

CVA Family Office’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$884 Sell
19
-9
-32% -$432 ﹤0.01% 1662
2026
Q1 		$1.45K Buy
28
+12
+75% +$611 ﹤0.01% 1585
2025
Q4 		$795 Hold
16
– – ﹤0.01% 1137
2025
Q3 		$765 Hold
16
– – ﹤0.01% 1171
2025
Q2 		$504 Hold
16
– – ﹤0.01% 1235
2025
Q1 		$524 Buy
+16
New +$567 ﹤0.01% 1244
2024
Q4 		– Sell
-14
Closed -$437 – 1340
2024
Q3 		$437 Buy
+14
New +$437 ﹤0.01% 1240

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

CVA Family Office's SUPN Position: Q2 2026 in Review

CVA Family Office reduced its Supernus Pharmaceuticals (SUPN) stake by 32% in Q2 2026, selling an estimated $432 and leaving 19 shares worth $884. The position accounts for ﹤0.01% of the portfolio, ranked #1662.

CVA Family Office first reported a position in SUPN in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.45K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • CVA Family Office held 19 shares of Supernus Pharmaceuticals worth $884 as of Q2 2026.
  • CVA Family Office sold 9 Supernus Pharmaceuticals shares in Q2 2026, an estimated $432.
  • Supernus Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1662 holding.
  • CVA Family Office first reported a position in Supernus Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • CVA Family Office's Supernus Pharmaceuticals position peaked at $1.45K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.